Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic ResponseFatima Karzai, William L. Dahut, James L. Gulley et al.|Clinical Cancer Research|2020Cited by 38
Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy for biochemically recurrent prostate cancer.Ravi A. Madan, James L. Gulley, Renee N. Donahue et al.|Journal of Clinical Oncology|2016Cited by 6
A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).Munjid Al Harthy, William L. Dahut, Ravi A. Madan et al.|Journal of Clinical Oncology|2019Cited by 3
Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.Gang Chen, Ravi A. Madan, David James VanderWeele et al.|Journal of Clinical Oncology|2019Cited by 3
Short course enzalutamide monotherapy in biochemically recurrent prostate cancer: Clinical and immunologic impact.Ravi A. Madan, James L. Gulley, Renee N. Donahue et al.|Journal of Clinical Oncology|2016Cited by 1